Udenyca 6 MG/0.6 ML syringe 0.6ML
Ended Awarded Last action
- Contract number
- SPE2DR26FQV7T
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $28,830
Award facts
- Contract value 100% obligated
- $28,829.65 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
This delivery order, valued at $28,829.65 with an ultimate completion date of February 2, 2026, awards pharmaceutical supplies to AmerisourceBergen Drug Corp for the delivery of Udenyca 6 mg/0.6 mL syringes. The contract was competitively awarded without set-aside designation to the Conshohocken, Pennsylvania-based pharmaceutical distributor and is funded by the Defense Logistics Agency (DLA), a component of the Department of Defense. This delivery order is executed under AmerisourceBergen's parent company Cencora, Inc.'s larger Indefinite Delivery Contract with DLA Troop Support Medical, valued at up to $999,999,999.00 through December 31, 2031, which serves as the primary vehicle for supplying comprehensive pharmaceutical products and medical supplies to support military healthcare programs globally.
AmerisourceBergen is a major pharmaceutical distributor that regularly fulfills federal medical procurement requirements for military and veteran healthcare systems through firm fixed-price delivery orders. The company's extensive portfolio includes specialty medications, brand-name and generic drugs, vaccines, and specialized medical supplies across multiple therapeutic domains. This specific award for Udenyca—a biosimilar filgrastim product used to manage chemotherapy-induced neutropenia—represents a routine pharmaceutical supply delivery under the broader strategic partnership that positions AmerisourceBergen as a critical vendor supporting the Defense Health Agency and U.S. Coast Guard healthcare operations.
Quick answers
Who was awarded contract SPE2DR26FQV7T?
SPE2DR26FQV7T was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 30, 2026.
How much is contract SPE2DR26FQV7T worth?
The government has obligated $28,830 on SPE2DR26FQV7T.
Is contract SPE2DR26FQV7T an order under another contract?
Yes. SPE2DR26FQV7T is a delivery order under SPE2DR25D1022, an indefinite delivery contract.
Was contract SPE2DR26FQV7T competed?
The extent of competition for SPE2DR26FQV7T was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award